Distinguishing Patients with Stage I Lung Cancer Versus Control Individuals using Serum Mass Profiling. (21st May 2014)

• Record Type: Journal Article
• Authors: Hanas, Jay S.; Peyton, Marvin D.; Lerner, Megan R.; Lightfoot, Stan A.; Deb, Subrato J.; Hanas, Rushie J.; Vu, Nicole T.; Kupiec, Thomas C.; Stowell, Donald E.; Brackett, Daniel J.; Dubinett, Steven M.; Hocker, James R.
• Is Part Of: Cancer investigation. Volume 32:Number 4(2014)
• Page Start: 136
• Page End: 143
• Publication Date: 2014-05-21
• Subjects: Lung cancer stage I -- Early detection -- Serum mass profiling -- Benign small pulmonary nodules -- Validation cohort; Cancer -- Periodicals; Oncology -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- Periodicals; 616.994
• DOI: 10.3109/07357907.2014.883528
• Languages: English
• ISSNs: 0735-7907

Abstract

Abstract : Serum mass profiling can discern physiological changes associated with specific disease states and their progression. Sera (86 total) from control individuals and patients with stage I nonsmall cell lung cancer or benign small pulmonary nodules were discriminated retrospectively by serum changes discerned by mass profiling. Control individuals were distinguished from patients with Stage I lung cancer or benign nodules with test sensitivities of 89% and 83%. Lung cancer patients versus those with benign nodules were distinguished with 80% sensitivity. This study exhibits progress toward a minimally-invasive aid in early detection of lung cancer and monitoring small pulmonary nodules for malignancy.